Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive,

Status Recruiting

Clinical Trial Summary

Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Clinical Trial Description

This is a non-randomized, multi-site, open-label Phase II trial for subjects with metastatic, hormone receptor positive, HER2 negative breast cancer. The study will enroll 47 patients to evaluate the anti-tumor activity of pembrolizumab with fulvestrant as measured by RECIST 1.1 tumor response and by progression free survival. We expect that if the immune response is augmented by the addition of pembrolizumab, significant change in durability of response will be noted.

Patients will be treated with pembrolizumab dosed at 200 mg intravenous infusion in combination with standard fulvestrant 500mg intramuscular injection. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03393845
Study type	Interventional
Source	Big Ten Cancer Research Consortium
Contact	Nancy Chan, MD
Phone	1 732-235-9692
Email	cheungna@cinj.rutgers.edu
Status	Recruiting
Phase	Phase 2
Start date	January 29, 2018
Completion date	January 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03095352` - A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease	Phase 2
Active, not recruiting	`NCT01472094` - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting	`NCT03284957` - Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT03544762` - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation	Phase 3
Completed	`NCT00341939` - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Active, not recruiting	`NCT01857193` - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer	Phase 1
Recruiting	`NCT03432429` - REI-EXCISE iKnife Study	N/A
Active, not recruiting	`NCT02139358` - Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer	Phase 1/Phase 2
Completed	`NCT03323333` - Psychosocial Intervention Pilot for Partners in BRCA Testing	N/A
Terminated	`NCT01649258` - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy	Phase 1
Completed	`NCT03384511` - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Phase 4
Recruiting	`NCT01992432` - Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
Completed	`NCT01943500` - Collection of Blood Specimens for Circulating Tumor Cell Analysis	N/A
Not yet recruiting	`NCT03433313` - Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer	Phase 3
Completed	`NCT02371174` - Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.
Not yet recruiting	`NCT03273348` - Role of Oncoplastic Breast Surgery In Breast Cancer Treatement	N/A
Active, not recruiting	`NCT02225470` - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	Phase 3
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Recruiting	`NCT03237572` - Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer	Phase 1
Recruiting	`NCT03324932` - Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms